Novel therapies for epilepsy in the pipeline.

Overview

Despite the availability of many antiepileptic drugs (AEDs) (old and newly developed) and, as recently suggested, their optimization in the treatment of patients with uncontrolled seizures, more than 30% of patients with epilepsy continue to experience seizures and have drug-resistant epilepsy; the management of these patients represents a real challenge for epileptologists and researchers. Resective surgery with the best rates of seizure control is not an option for all of them; therefore, research and discovery of new methods of treating resistant epilepsy are of extreme importance. In this article, we will discuss some innovative approaches, such as P-glycoprotein (P-gp) inhibitors, gene therapy, stem cell therapy, traditional and novel antiepileptic devices, precision medicine, as well as therapeutic advances in epileptic encephalopathy in children; these treatment modalities open up new horizons for the treatment of patients with drug-resistant epilepsy.

https://vivo.med.cornell.edu/individual/pubid31284159authorship1 Associate Professor of Clinical Neurology
https://vivo.med.cornell.edu/individual/pubid31284159authorship2
https://vivo.med.cornell.edu/individual/pubid31284159authorship3
https://vivo.med.cornell.edu/individual/pubid31284159authorship4
https://vivo.med.cornell.edu/individual/pubid31284159authorship5
https://vivo.med.cornell.edu/individual/pubid31284159authorship6
https://vivo.med.cornell.edu/individual/pubid31284159authorship7
https://vivo.med.cornell.edu/individual/pubid31284159authorship8